申请人:DANA-FARBER CANCER INSTITUTE, INC.
公开号:US20210094913A1
公开(公告)日:2021-04-01
The disclosure relates to a compound having Formula (I′):
and
in particular, Compound I-126:
which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.